On February 12, 2024, Chugai, Genentech, and Hoffmann-La Roche filed a motion for voluntary dismissal of their appeals of the PTAB’s Final Written Decisions in IPR2022-00578 and IPR2022-00579. The appeals concerned IPRs filed by Celltrion where the PTAB found all challenged claims of U.S. Patent Nos. 8,580,264 and 10,874,677 were either anticipated by or
Latest Post
More Posts
Update on Ophthalmic Anti-VEGF Therapeutics
Update: Post-Trial Briefing in Regeneron v. Mylan Aflibercept BPCIA Case Now Complete
FDA Accepts Xbrane’s sBLA for LUCENTIS® (Ranibizumab) Biosimilar Candidate
Amneal Launches FYLNETRA (pegfilgrastim-pbbk) in the United States
Mabwell Announces Approval of Denosumab Biosimilar MAILISHU in China
Biosimilar Clinical Trial Updates
FDA Approves EYLEA® (Aflibercept) for Treatment of Retinopathy of Prematurity
Amgen Launches AMJEVITA—First Biosimilar to HUMIRA in the United States
PTAB Issues Final Written Decisions Finding Claims of Regeneron’s Aflibercept Patents Invalid
Subscribe: Subscribe via RSS
Blogs
Firm/Org